Gastrointestinal Cancer Drugs Market is segmented By Therapy (Targeted Therapy, Chemotherapy, Radiation therapy, Surgery, Others), By End-users (Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Clinics, Others), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Gastrointestinal Cancer Drugs Market Overview
Gastrointestinal Cancer Drugs Market is expected to grow at a CAGR of 5% during the forecast period (2024-2031).
Cancer of the gastrointestinal tract (GI tract) and its auxiliary organs of digestion, such as the oesophagus, stomach, biliary system, pancreas, small intestine, large intestine, rectum, and anus, are together referred to as gastrointestinal cancer.
Gastrointestinal Cancer Drugs Market Scope
| Metrics | Details |
| Market CAGR | 5% |
| Segments Covered | By Therapy, By End-user, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For more Insights - Request Free Sample
Gastrointestinal Cancer Drugs Market Dynamics
The increasing research and development are expected to drive the market growth
The factors influencing the global gastrointestinal cancer drugs market are the increasing research and development and the growing prevalence of gastrointestinal cancer. This type of cancer is also referred to as Stomach Cancer.
In recent years, the treatment of GI cancer has advanced due to immunotherapy and targeted therapy. Since PD-1/PD-L1 antibodies or targeted therapies (such as bevacizumab and cetuximab) for advanced GI cancers were approved by the Food and Drug Administration (FDA) or National Medical Products Administration (NMPA), this approval has also encouraged the development of other novel products. The development of new therapies for GI cancer, particularly upper GI cancer, has lagged far behind lung cancer or melanoma. Immunotherapy and targeted therapy have rapidly advanced in treating GI cancer in recent years.
Since the Food and Drug Administration (FDA) or National Medical Products Administration (NMPA) approved PD-1/PD-L1 antibodies or targeted treatments (such as bevacizumab and cetuximab) for advanced GI malignancies, this approval has also stimulated the creation of other novel products. However, the discovery of novel treatments for GI cancer, particularly upper GI cancer, has lagged significantly compared to lung cancer or melanoma. Additionally, Chinese biopharmaceutical businesses have not widely used the optimization of therapeutic R&D using cutting-edge technologies and concepts, such as artificial intelligence, antibody-dependent cell-mediated cytotoxicity (ADCC), and proteolysis targeting chimeras’ mechanism. The results and quality of life of GI cancer patients may be improved with improved biopharmaceutical R&D and cost-effective cancer medications.
The limitations associated with gastrointestinal cancer drugs are expected to hamper the Gastrointestinal Cancer Drugs Market growth
Despite the growing number of fundamental investigations into GI cancer in preclinical research, most of these beachside findings failed to provide any notable bedside outcomes, emphasizing the need for high-quality translational studies. A robust translational pipeline is required to advance each stage of the translation process. The ideal translational platform has a biobank that stores blood, biopsy samples, and ascites from GI cancer patients, preclinical patient-derived xenografts (PDX), immune-humanized models, and these features.
The bench side-bedside-bench side paradigm should be used to guide translational studies and the examination of new medications at the clinical level to promote preclinical-to-clinical translatability. Certain clinical issues are specific to GI cancer.
Industry Analysis
The global gastrointestinal cancer drugs market provides in-depth analysis of the market based on various industry factors such as porter’s five forces, regulatory analysis, reimbursement scenario, pipeline analysis, pricing analysis, etc.
COVID-19 Impact Analysis
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes Corona Virus Disease 2019 (COVID-19) has spread globally. The SARS-CoV-2 infection in patients with gastric cancer, the third-leading cause of mortality worldwide, presents a significant problem for managing the patients' health. Drugs targeting critical proteins of both SARS-CoV-2 and GC must be urgently repurposed because it has been difficult to produce a new treatment for COVID-19. People with cancer are among the most vulnerable groups in this (COVID-19) epidemic, and treating these patients is extremely difficult.
Over 1 million individuals are diagnosed with GC annually, making it a global health crisis. Additionally, gastric mucosa and GI tract cells have been found to contain the SARS-CoV-2 receptor ACE2, which suggests that these tissues may be particularly susceptible to SARS-CoV-2 infection. The persistent presence of the virus in the gastric mucosa suggests that the virus may have infected gastric glandular epithelial cells. Therefore, it is crucial to treat GC patients with COVID-19.
Gastrointestinal Cancer Drugs Market Segmentation Analysis
The targeted therapy segment is expected to dominate the market growth
The third most common cancer that results in death is gastric cancer. New treatments are urgently required because traditional chemotherapy has demonstrated minimal success (with a median overall survival of 10 months), and surgery is the sole curative treatment option. The only targeted treatments that have been approved so far are Trastuzumab and Ramucirumab, which target HER2 and VEGFR2, respectively. Drugs known as targeted cancer therapies specifically target elements in cancer cells, such as proteins or genes, that promote the growth and metastasis of the disease. They might potentially target other cell types that aid in the development and spread of cancer.
Targeted therapy may be more effective than other treatments for specific cancer types. More than 15 different cancers, including those of the breast, prostate, colon, and lung, have received FDA approval for targeted therapy. However, they are only effective if the tumor has the correct target. Additionally, if the target changes or cancer develops a resistance to the treatment, targeted therapies frequently stop working. More knowledge is being gained about the alterations that cause cancer. Future targeted medicines might be improved because of this.
Gastrointestinal Cancer Drugs Market Geographical Share
The North America region is expected to hold the largest market share in the global gastrointestinal cancer drugs market
The increasing research and development and growing prevalence of gastrointestinal cancer is expected to drive the market growth in this region.
According to the American Cancer Society, there will likely be about 26,380 cases of stomach cancer (also known as gastric cancer) in the US in 2022. (15,900 in men and 10,480 in women) 11,090 people died from this cancer (6,690 men and 4,400 women). Approximately 1.5% of all new cancer cases identified yearly in the US are stomach cancer. In the United States, stomach cancer will be discovered in an estimated 26,380 people this year (15,900 males and 10,480 women). In 2020, the disease will have affected 1,089,103 individuals worldwide. The fifth most frequent cancer in the world is stomach cancer.
Gastrointestinal Cancer Drugs Market Companies
The global gastrointestinal cancer drugs market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Novartis AG, Amgen, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Johnson & Johnson Private Limited, GlaxoSmithKline plc., Celgene Corporation, Pfizer Inc, Sanofi
Novartis AG
Overview: Novartis International AG is an international pharmaceutical company with offices in Basel, Switzerland, and Cambridge, Massachusetts, the United States. The company is one of the biggest in the pharmaceutical industry. The company was founded in 1996.
Product Portfolio: Adults with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including GEP-NETs in the foregut, midgut, and hindgut, are positive for the hormone receptor somatostatin and are treated with LUTATHERA (lutetium Lu 177 dotatate) injection for intravenous administration.
Key Development: On 26th January 2018, the U.S. Food and Drug Administration approved Lutathera (lutetium Lu 177 dotatate) for the treatment of gastroenteropancreatic neuroendocrine tumors, a kind of cancer that affects the pancreas or gastrointestinal tract (GEP-NETs). The therapy of GEP-NETs using a radioactive medication, or radiopharmaceutical, has never been authorized before. Adult patients with GEP-NETs that are somatostatin receptor-positive are eligible for lutathera.
